UPDATE: Guggenheim Reiterates Alnylam Pharmaceuticals As Top Pick As Firm Continues 'to think the Onpattro launch will go well given the existing pool of identified patients and Onpattro's profile vs. competitors'; Reiterates Buy, $105 Target